Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14268959 | 0.87 | HTT (0.43) | KMT2AMAPK1HTTGAACREBBP | |
| SCHEMBL4866820 | 0.84 | KMT2A (0.46) | KMT2AMAPK1HTTGAACREBBP | |
| SCHEMBL14268987 | 0.83 | CREBBP (0.43) | HTTCREBBP | |
| SCHEMBL14269002 | 0.81 | RAB9A (0.39) | KMT2AHTTCREBBPHSD17B10HTR1A | |
| SCHEMBL4869066 | 0.81 | TLR8 (0.43) | — | |
| SCHEMBL28794758 | 0.76 | CYP2A6 (0.41) | KMT2AMAPK1HSD17B10 | |
| SCHEMBL8086804 | 0.75 | CYP2E1 (0.58) | KMT2AMAPK1HTTGAAHTR1A | |
| SCHEMBL8445961 | 0.75 | CREBBP (0.50) | KMT2ACREBBP | |
| SCHEMBL5092010 | 0.74 | PRKD3 (0.55) | KMT2AHTTCREBBP | |
| SCHEMBL3634653 | 0.72 | QPCT (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332476-B2 | Pyridyl substituted ketolide antibiotics | NOVARTIS AG (CH) | 2008-02-19 | — | — | US | disclosed |
| EP-1618119-A2 | PYRIDYL SUBSTITUTED KETOLIDE ANTIBIOTICS | CHIRON CORPORATION (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20050009764-A1 | Pyridyl substituted ketolide antibiotics | CHIRON CORPORATION (US) | 2005-01-13 | — | — | US | disclosed |
| WO-2004096822-A2 | PYRIDYL SUBSTITUTED KETOLIDE ANTIBIOTICS | CHIRON CORPORATION (US) | 2004-11-11 | — | — | WO | disclosed |
| US-6756359-B2 | ADMINISTERING A 14 MEMBERED MACROLIDE AND KETOLIDE ANTIBIOTICS CONTAINING C12 MODIFICATIONS TO A PATIENT SUFFERING FROM BACTERIAL INFECTIONS | CHIRON CORPORATION | 2004-06-29 | — | — | US | disclosed |
| EP-1404693-A2 | C12 MODIFIED ERYTHROMYCIN MACROLIDES AND KETOLIDES HAVING ANTIBACTERIAL ACTIVITY | CHIRON CORPORATION (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030125266-A1 | C12 Modified erythromycin macrolides and ketolides having antibacterial activity | CHU DANIEL (US) | 2003-07-03 | — | — | US | disclosed |
| WO-2003004509-A2 | C12 MODIFIED ERYTHROMYCIN MACROLIDES AND KETOLIDES HAVING ANTIBACTERIAL ACTIVITY | CHIRON CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009764-A1 | Pyridyl substituted ketolide antibiotics | PKLR, KHK, PGD | KMT2A 2250/4885MAPK1 1652/4885HTT 4317/4885 |
| US-20030125266-A1 | C12 Modified erythromycin macrolides and ketolides having antibacterial activity | MRPL21, CYP51A1, CEL | KMT2A 1920/4885MAPK1 1687/4885HTT 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.